List view / Grid view
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
In this Q&A, Dr Murray Cairns, NHMRC Leadership Research Fellow at the University of Newcastle, shares his insights about the genetic influences on circulating retinol, and explains how a retinol polygenic score could be utilised in a precision medicine approach.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have developed the world’s first animal model with A-to-G mtDNA edits achieved using engineered TALEDs.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
Using tumour organoids, researchers identified that overexpression of Engrailed-1 blocked genes associated with natural cell death.
By studying the molecular cell states within transplanted paediatric hearts, researchers have unlocked new treatment strategies.
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
